依达拉奉联合奥扎格雷、低分子肝素治疗急性脑梗死180例疗效评价

目的:探讨依达拉奉、奥扎格雷、低分子肝素联合应用治疗脑梗死的临床疗效。方法:选取急性脑梗死患者180例,随机分为对照组(90例)和治疗组(90例),均使用复方丹参注射液作为基础治疗。治疗组加用依达拉奉和奥扎格雷静滴、低分子肝素皮下注射联合治疗;对照组只使用依达拉奉静滴治疗。观察14天和30天后,神经功能缺损程度评分(NIHSS)和日常生活能力评分(ADL),同时观察治疗前后血小板和凝血四项的不同变化。结果:治疗组比对照组的神经功能缺损程度评分明显降低,而日常生活能力评分明显提高。同时对比对照组的血小板计数减少,凝血时间延长。均具有显著性差异(P<0.05)。结论:使用依达拉奉、奥扎格雷、低分子肝素联合治疗,比单纯使用依达拉奉治疗效果好,并且安全有效,值得推广。

Objective： To study the clinical effect of edaravone combination therapy with ozagrel and low molecular heparin for acute cerebral infarction. Methods ： The case - control trail was carried out 180 inpatients of acute cerebral infarction. They were randomly divided into a treatment group and a control group. The two groups both were given casual treatment and edaravone intravenous drip. The patients in treatment group were given ozagrel intravenous drip and low molecular heparin subcutaneous injection. The control group only received edaravone. The index included National Institutes of Health Stroke（NIHSS） and Barthel exponent of different time （ day14, day30 ）. At the same time coagulation four indices （PT, APTT, TT and FIB） and PLT were determined. Results： Compared with control group, NIHSS was significantly decreased and Barthel exponent was increased at day 14 and 30 after the treatment （ P 〈 0. 05 ）. The levels of PLT, PT,TT, APTT and FIB in the treatment group have a prominent difference,compared with the control group （ P 〈 0.05 ）. Conclusions：The combination therapy was evidently effective and safe, which is worthwhile to spread around.